Welcome to Sequence Card of Peptide


Details of CancerPDF entry with Sequence RPPGFSPF
Primary information
sequence IDSeq_6690
Peptide sequenceRPPGFSPF
CancerPDF_ID CancerPDF_ID91, CancerPDF_ID161, CancerPDF_ID740, CancerPDF_ID1088, CancerPDF_ID1897, CancerPDF_ID3225, CancerPDF_ID8631, CancerPDF_ID9450, CancerPDF_ID9937, CancerPDF_ID12742, CancerPDF_ID12996, CancerPDF_ID12997,
PMID16896061,19728888,19795908,16395409,21136997,21136997,24416269,26379225,21124649,27058005,20974924,20974924
Protein NameBradykinin (and des-Arg bradykinin),Bradykinin,Kininogen-1,Bradykinin (and des-Arg bradykinin),Kininogen-1,Kininogen-1,"kininogen L,high MW",Des-Arg9 Bradykinin,Kininogen-1,Kininogen-1,Kininogen-1,Kininogen-1
UniprotKB Entry NameBKRB2_HUMAN,BKRB2_HUMAN,KNG1_HUMAN,BKRB2_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN,KNG1_HUMAN
FluidSerum,Serum,Plasma,Serum,Serum,Plasma,Plasma,Plasma,Serum,Serum,Plasma,Plasma
M/Z904.48,904.4726,452.74,904.48,903.46029,903.4603,904.53,904.46,NA,904.5017,904.468,904.468
Charge1,NA,2,1,1,1,NA,NA,NA,NA,2,2
Mass (in Da)904.46,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
fdrNA,NA,NA,NA,NA,NA,NA,NA,904.1,NA,NA,NA
Profiling TechniqueMALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS,MALDI-TOF,MALDI-TOF,LC-MS,MALDI-TOF,LC-MS,LC-MS
Peptide Identification techniqueQ/TOF MS/MS,LC-MS/MS,MALDI-TOF/TOF,Q/TOF/TOF and LC-MS/MS,LC-MS-MS/MS,LC-MS-MS/MS,MS/MS,MALDI-TOF/TOF,LC-ESI-MS/MS,LC-MS/MS,LC-MS/MS,LC-MS/MS
Quantification TechniqueNA,NA,LC-MRM (multiple reaction monitoring),NA,LC-ESI-MS,LC-ESI-MS,Affinity Chromatography,NA,NA,NA,NA,NA
Labelled/Label FreeLabel Free,Label Free,Labelled,Label Free,Label Free,Label Free,Label Free,Label Free,Labelled,Label Free,Label Free,Label Free
FDRNA,NA,less than 7%,less than 1 “5,NA,NA,NA,NA,NA,NA,NA,NA
CancerPDF_ID CancerPDF_ID91, CancerPDF_ID161, CancerPDF_ID740, CancerPDF_ID1088, CancerPDF_ID1897, CancerPDF_ID3225, CancerPDF_ID8631, CancerPDF_ID9450, CancerPDF_ID9937, CancerPDF_ID12742, CancerPDF_ID12996, CancerPDF_ID12997,
p-Value1.00E-05,5.45E-04,NA,3.65E-14,NA,NA,less than 0.05,NA,NA,"less than 0.01,less than 0.05,0.662",NA,NA
SoftwareMASCOT,MASCOT(v 2.0.04 for Windows),FlexAnalysis 3.0 and Biotools 3.0 software,MASCOT (v 2.0.04 for Windows),MASCOT(v. 2.2.01),MASCOT(v. 2.2.01),MASCOT and Markerview software version 1.2,MASCOT (v 2.3),NA,Proteome Discoverer,MASCOT and SEQUEST,MASCOT and SEQUEST
Length8,8,8,8,8,8,8,8,8,8,NA,NA
Cancer TypeMetastatic thyroid carcinomas,"Non-small cell lung cancer (NSCLC) patients, who were treated with first-line chemotherapy",Ductal adenocarcinoma of the pancreas (DAP),"Advanced Prostate, Breast and Bladder cancer",Colorectal cancer,Normal,Cervical cancer,Colorectal cancer,Breast cancer,Breast cancer,"Multiple myeloma patients, Acute myeloid leukemia","Multiple myeloma patients, Acute myeloid leukemia"
DatabaseNCBI refseq Protein Database,SwissProt Database (release 54.7),NCBI refseq Protein Database,NCBI refseq Protein Database,SwissProt Database,SwissProt Database,NA,UniprotKB,NCBI Protein Database,SwissProt Database,Uniprot database,Uniprot database
ModificationNA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
Number of Patients40 metastatic thyroid carcinoma patients and 40 normal for training phase and 10 metastatic thyroid carcinoma and 10 normal individuals for independent validation,"11 NSCLC patients with the shortest PFS, 11 patients with the longest PFS","42 normal, 25 patients","Advanced prostate (n = 32), breast (n = 21), and bladder (n = 20) cancer, 33 healthy in training test set, In validation set 41 independent serum samples from patients with advanced prostate cancer (prostate 2 [PR2])",30 patients and 30 healthy controls,27 healthy individuals,67 patients and 4 healthy,"94 patients with CRC, 23 with liver metastasis from CRC (histologically defined) and 34 subjects, which underwent colonoscopy and resulted negative",9 BC and 9 control," 28 were diagnosed with Breast cancer, 27 remained cancer-free with BRCA carrier. Of the remaining patients, 39 were diagnosed with sporadic breast cancer (SBC), and 38 were healthy volunteers (WT).",NA,NA
RegulationNA,Peptide Ion Signature for differentiation between Short PFS(Progression Free survival) versus long PFS,NA,"For bladder (Lower) and for breast (Higher) Differential ion intensity in cancer compare to normal with Ratio of median intensity (patients/Controls) =1.06, 0.79 and 1.62 in prostate, bladder and breast cancer respectively",NA,NA,Uniquely present in cervical cancer,Higher median intensity for liver metastasis group and lower median intensity for adenoma and CRC groups than the controls. ,NA,"Upregulated with the fold change of 0.29 in breast cancer vs Cancer free patients with brca mutation, Upregulated in breast cancer vs sporadic breast cancer with fold change of 1.40, Upregulated in BC vs healthy with 0.902 fold change",NA,NA
ValidationIndependent validation,Independent validation,NA,Independent validation,Leave One out Cross validation,Leave One out Cross validation,NA,NA,NA,NA,NA,NA
Sensitivity95% on independent dataset,1,NA,97.5% on independent validation dataset,NA,NA,NA,NA,NA,NA,NA,NA
Specificity95% on independent dataset,0.73,NA,NA,NA,NA,NA,NA,NA,NA,NA,NA
AccuracyNA,0.86,NA,97.5 % on validation dataset,NA,NA,NA,NA,NA,NA,NA,NA
Peptide AtlasPeptideAtlas
IEDB